AlzChem Group Crecimiento futuro
Future controles de criterios 4/6
Se prevé un crecimiento anual de los beneficios y los ingresos de AlzChem Group de 19.6% y 11.5% por año respectivamente. Se prevé que el BPA crezca en un 19.8% al año. Se espera que la rentabilidad financiera sea de 26% en 3 años.
Información clave
19.6%
Tasa de crecimiento de los beneficios
19.83%
Tasa de crecimiento del BPA
| Crecimiento de los beneficios de Chemicals | 11.6% |
| Tasa de crecimiento de los ingresos | 11.5% |
| Rentabilidad financiera futura | 26.04% |
| Cobertura de analistas | Good |
| Última actualización | 11 Aug 2026 |
Actualizaciones recientes sobre el crecimiento futuro
Recent updates
Actualización de narrativa • Jul 21
ACT: Integrated Calcium Chain And US Expansion Will Support Future Cash Flows
Analysts have raised their fair value estimate for AlzChem Group to about €254 from €200, citing recent research that highlights the company’s unique position in the calcium carbide and calcium cyanide value chain, along with updated assumptions for revenue growth, profit margins, and future P/E levels. Analyst Commentary Bullish analysts covering AlzChem Group highlight the company’s role in the calcium carbide and calcium cyanide value chain as a key support for current fair value assumptions and recent target price work.
Actualización de narrativa • Jul 07
ACT: Niche Calcium Chain Platform And Dividend Policy Will Shape 2026 Outlook
The analyst price target for AlzChem Group has increased from €192.07 to €204.49, with analysts citing the company's unique position in the calcium carbide and calcium cyanide value chain, along with recent supportive research, as key factors behind the revision. Analyst Commentary Recent research coverage on AlzChem Group highlights a mix of supportive and cautious views as analysts reassess where the stock should trade, with an emphasis on the company’s role in the calcium carbide and calcium cyanide value chain and how effectively it can convert that position into sustainable execution.
Actualización de narrativa • Jun 23
ACT: Specialty Platform And Value Chain Position Will Shape Cash Flow And Dividend
Analysts have lifted their price target on AlzChem Group by €4, from €173 to €177, citing recent research that highlights the company’s unique position in the calcium carbide and calcium cyanide value chain, as well as updated assumptions on discount rate, revenue growth, profit margin and forward P/E. Analyst Commentary Recent research on AlzChem Group highlights the company’s role in the calcium carbide and calcium cyanide value chain, but not all commentary is upbeat.Actualización de narrativa • Jun 08
ACT: Specialty Chemicals Platform And Shareholder Moves Will Shape 2026 Outlook
Analysts have lifted their price targets on AlzChem Group by about €7 per share to roughly €192. This reflects updated views on fair value, discount rate assumptions and profitability that are broadly in line with recent research from Jefferies and Berenberg.Actualización de narrativa • May 24
ACT: Specialty Chemicals Moat And 2026 Expansions Will Support Future Cash Generation
Narrative Update on AlzChem Group The analyst price target for AlzChem Group has moved higher to €200, with analysts pointing to recent research that highlights confidence in the company’s specialty chemicals focus and its potential for high margin projects and cash generation in the coming years. Analyst Commentary Recent research shows a clear uptick in confidence from bullish analysts, with several price target revisions pointing to stronger conviction around AlzChem Group's specialty chemicals focus and project pipeline.Artículo de análisis • May 08
Investors Shouldn't Be Too Comfortable With AlzChem Group's (ETR:ACT) Earnings
Despite announcing strong earnings, AlzChem Group AG's ( ETR:ACT ) stock was sluggish. Our analysis uncovered some...Actualización de narrativa • May 01
ACT: Specialty Chemicals Moat And 2026 Expansions Will Drive Future Upside
Narrative update on AlzChem Group The analyst fair value estimate for AlzChem has been lifted by €5 to €200, with analysts citing recent price target increases from multiple firms and reinforcing views around the company's specialty chemicals focus, margin profile and potential long term value creation. Analyst Commentary Bullish analysts have been steadily lifting their price targets for AlzChem, pointing to the specialty chemicals focus and the margin profile as key supports for higher valuations.Actualización de narrativa • Apr 17
ACT: Specialty Platform And 2026 Expansions Will Underpin Cash Flow And Dividend Potential
Analysts have lifted their price targets on AlzChem to a range of about €195 to €197, reflecting updated models that incorporate a slightly lower discount rate, modestly higher revenue growth and profit margin assumptions, and a marginally reduced future P/E. Analyst Commentary Recent research points to a broadly constructive stance on AlzChem Group, with several firms lifting price targets into a narrow band between about €195 and €197.Actualización de narrativa • Apr 03
ACT: Specialty Platform And 2026 Expansions Will Support Measured Long Term Upside Potential
The updated analyst price target for AlzChem Group has moved from €165 to €173, as analysts point to recent target increases on the Street and renewed confidence in the company's specialty chemicals focus and niche production platform. Analyst Commentary Recent Street research has centered on higher price targets for AlzChem Group, with several firms highlighting the specialty chemicals profile and niche positioning as key supports for their views.Actualización de narrativa • Mar 20
ACT: Specialty Chemicals Platform And 2026 Expansion Plans Will Support Upside
Analysts have lifted the implied fair value estimate for AlzChem Group to about €185 from roughly €177, supported by higher Street price targets in the €195 to €197 range and confidence in the company's specialty chemicals focus and production platform. Analyst Commentary Recent research updates point to a constructive tone from bullish analysts, who see the higher price targets as aligned with confidence in AlzChem Group's business model and execution around specialty chemicals.Actualización de narrativa • Mar 06
ACT: Specialty Chemicals Moat And 2026 Projects Will Drive Future Upside
Narrative Update on AlzChem Group The analyst price target for AlzChem Group has moved from €185 to €195, with analysts highlighting the company's specialty chemicals performance, unique production platform and high margin growth projects as key factors in their updated view. Analyst Commentary Bullish analysts are leaning into a constructive view on AlzChem Group, pointing to recent research updates as support for higher valuation expectations and confidence in the company’s execution.Actualización de narrativa • Feb 19
ACT: New Creatine Capacity Plan Will Support Measured Long Term Upside Potential
Analysts are holding their price target for AlzChem Group steady at €165.00. They explain the unchanged view by pointing to updated assumptions that combine a slightly higher discount rate and P/E multiple with adjusted revenue growth and profit margin expectations.Actualización de narrativa • Feb 05
ACT: New Creatine Investment Program Will Support Long Term Upside Potential
Analysts have lifted their price target on AlzChem Group from €150.00 to €165.00, citing updated assumptions around revenue growth, profit margins, and a lower future P/E multiple in their models. What's in the News AlzChem Group AG has approved an investment program of around €120 million aimed at supporting additional profitable growth and reinforcing its presence in specialty chemicals for sports, food, and health (company announcement).Artículo de análisis • Jan 23
Is AlzChem Group AG (ETR:ACT) Trading At A 33% Discount?
Key Insights AlzChem Group's estimated fair value is €231 based on 2 Stage Free Cash Flow to Equity Current share price...Actualización de narrativa • Jan 21
ACT: New Creatine Plant And 2025 Outlook Will Underpin Balanced Prospects
Analysts have modestly trimmed their price target for AlzChem Group to €176.94 from €179.93 as minor adjustments to the discount rate, revenue growth assumptions, profit margin outlook and future P/E expectations feed into a slightly lower fair value estimate. What's in the News AlzChem Group AG approved an investment program of around €120 million to build a more automated production plant for creatine and its precursors, along with related infrastructure, targeting additional growth in sports, food and health (Key Developments).Actualización de narrativa • Jan 07
ACT: New Creatine Capacity Expansion And 2025 Record Outlook Will Support Upside
Analysts now set a higher fair value target for AlzChem Group at €179.93 compared with €167.10 previously. They point to updated assumptions for revenue growth, profit margins and a lower future P/E multiple.Actualización de narrativa • Dec 16
ACT: New Creatine Capacity And Partnerships Will Support Balanced Long Term Outlook
Analysts have raised their price target for AlzChem Group from €97.00 to €150.00, citing slightly stronger expectations for long term revenue growth and a higher justified future P E multiple, despite a modestly lower profit margin outlook. What's in the News AlzChem Group has approved an approximately EUR 120 million investment program to build a more automated creatine production plant and related infrastructure, targeting additional annual sales in the early triple-digit million euro range.Actualización de narrativa • Dec 02
ACT: Earnings Guidance And New Product Launch Will Drive Record Performance
Analysts have maintained their price target for AlzChem Group at €167.10. They cite steady outlooks for revenue growth and profit margins, with only minor adjustments to the discount rate and future earnings projections.Artículo de análisis • Nov 24
AlzChem Group AG's (ETR:ACT) Business Is Trailing The Market But Its Shares Aren't
With a price-to-earnings (or "P/E") ratio of 21.1x AlzChem Group AG ( ETR:ACT ) may be sending bearish signals at the...Actualización de narrativa • Nov 18
ACT: Strong Revenue Outlook And Product Launches Will Drive Upside Momentum
Analysts have raised their price target for AlzChem Group from €163.10 to €167.10, citing improved revenue growth forecasts. These improved forecasts have offset slight adjustments in the discount rate and profit margin expectations.Actualización de narrativa • Nov 02
ACT: Profitability Improvements And Product Launch Partnerships Will Support Fair Valuation
Analysts have raised their price target for AlzChem Group from €154.24 to €163.10. They cite improved profit margin projections and continued confidence in the company's financial outlook.Artículo de análisis • Oct 13
AlzChem Group AG (ETR:ACT) Shares Could Be 34% Below Their Intrinsic Value Estimate
Key Insights AlzChem Group's estimated fair value is €236 based on 2 Stage Free Cash Flow to Equity AlzChem Group's...Artículo de análisis • Sep 13
Is AlzChem Group (ETR:ACT) Using Too Much Debt?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Actualización de narrativa • Aug 20
Global Nutrition Trends And Capacity Expansions Will Unlock Opportunities
The increase in AlzChem Group’s consensus price target is primarily driven by a higher forward P/E multiple rather than changes in revenue growth forecasts, with fair value rising from €135.24 to €143.64. What's in the News AlzChem Group AG confirmed its full-year 2025 guidance, projecting organic sales growth of approximately 5% to around EUR 580 million.Artículo de análisis • Aug 20
Is Now An Opportune Moment To Examine AlzChem Group AG (ETR:ACT)?
While AlzChem Group AG ( ETR:ACT ) might not have the largest market cap around , it received a lot of attention from a...Actualización de narrativa • Aug 06
Global Nutrition Trends And Capacity Expansions Will Unlock Opportunities
AlzChem Group's higher consensus price target reflects improved profitability and a lower forward P/E, indicating stronger earnings expectations and valuation support, with fair value raised from €124.40 to €135.24. What's in the News AlzChem Group AG confirmed full year 2025 guidance, expecting approximately 5% organic sales growth to around EUR 580 million.Artículo de análisis • Aug 02
AlzChem Group AG Just Missed Earnings And Its Revenue Numbers Were Weaker Than Expected
Investors in AlzChem Group AG ( ETR:ACT ) had a good week, as its shares rose 4.0% to close at €156 following the...Artículo de análisis • Jul 22
AlzChem Group AG (ETR:ACT) Stock Rockets 25% As Investors Are Less Pessimistic Than Expected
AlzChem Group AG ( ETR:ACT ) shares have continued their recent momentum with a 25% gain in the last month alone. The...Artículo de análisis • Jun 02
Returns Are Gaining Momentum At AlzChem Group (ETR:ACT)
If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...Artículo de análisis • May 19
A Look At The Fair Value Of AlzChem Group AG (ETR:ACT)
Key Insights AlzChem Group's estimated fair value is €119 based on 2 Stage Free Cash Flow to Equity AlzChem Group's...Artículo de análisis • May 05
What AlzChem Group AG's (ETR:ACT) 29% Share Price Gain Is Not Telling You
Despite an already strong run, AlzChem Group AG ( ETR:ACT ) shares have been powering on, with a gain of 29% in the...Artículo de análisis • May 03
AlzChem Group's (ETR:ACT) Dividend Will Be Increased To €1.80
AlzChem Group AG ( ETR:ACT ) will increase its dividend from last year's comparable payment on the 13th of May to...Artículo de análisis • May 01
Is It Too Late To Consider Buying AlzChem Group AG (ETR:ACT)?
AlzChem Group AG ( ETR:ACT ), might not be a large cap stock, but it received a lot of attention from a substantial...Artículo de análisis • Mar 28
AlzChem Group's (ETR:ACT) Dividend Will Be Increased To €1.80
The board of AlzChem Group AG ( ETR:ACT ) has announced that it will be paying its dividend of €1.80 on the 13th of...Artículo de análisis • Mar 18
With EPS Growth And More, AlzChem Group (ETR:ACT) Makes An Interesting Case
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...Artículo de análisis • Mar 05
AlzChem Group AG (ETR:ACT) Just Reported And Analysts Have Been Lifting Their Price Targets
Investors in AlzChem Group AG ( ETR:ACT ) had a good week, as its shares rose 6.3% to close at €77.80 following the...Artículo de análisis • Mar 03
AlzChem Group's (ETR:ACT) Dividend Will Be Increased To €1.80
AlzChem Group AG's ( ETR:ACT ) periodic dividend will be increasing on the 13th of May to €1.80, with investors...Artículo de análisis • Feb 19
Market Still Lacking Some Conviction On AlzChem Group AG (ETR:ACT)
With a price-to-earnings (or "P/E") ratio of 14.1x AlzChem Group AG ( ETR:ACT ) may be sending bullish signals at the...
Nueva narrativa • Feb 17
Expansion Of Nitroguanidine Production To Meet Defense Industry Demand Is Expected To Strengthen Market Position
Strategic expansion in production capacities and collaboration with the U.S. Department of Defense could bolster long-term revenue and market diversification.Artículo de análisis • Nov 14
AlzChem Group's (ETR:ACT) Earnings May Just Be The Starting Point
AlzChem Group AG ( ETR:ACT ) just reported healthy earnings but the stock price didn't move much. Investors are...Artículo de análisis • Oct 27
AlzChem Group AG's (ETR:ACT) Shares Leap 26% Yet They're Still Not Telling The Full Story
AlzChem Group AG ( ETR:ACT ) shareholders would be excited to see that the share price has had a great month, posting a...Artículo de análisis • Oct 18
When Should You Buy AlzChem Group AG (ETR:ACT)?
AlzChem Group AG ( ETR:ACT ), might not be a large cap stock, but it saw a significant share price rise of 46% in the...Artículo de análisis • Sep 07
AlzChem Group (ETR:ACT) Has A Pretty Healthy Balance Sheet
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Artículo de análisis • Jun 04
A Look At The Intrinsic Value Of AlzChem Group AG (ETR:ACT)
Key Insights Using the 2 Stage Free Cash Flow to Equity, AlzChem Group fair value estimate is €43.94 AlzChem Group's...Artículo de análisis • May 08
AlzChem Group's (ETR:ACT) Earnings Seem To Be Promising
AlzChem Group AG's ( ETR:ACT ) recent earnings report didn't offer any surprises, with the shares unchanged over the...Previsiones de crecimiento de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Flujo de caja libre | Flujo de caja operativo | Núm. de analistas medio |
|---|---|---|---|---|---|
| 12/31/2028 | 803 | 106 | 87 | 116 | 7 |
| 12/31/2027 | 705 | 83 | -22 | 95 | 8 |
| 12/31/2026 | 608 | 66 | -9 | 141 | 8 |
| 6/30/2026 | 594 | 68 | -22 | 116 | N/A |
| 3/31/2026 | 581 | 67 | 4 | 125 | N/A |
| 12/31/2025 | 575 | 63 | 39 | 137 | N/A |
| 9/30/2025 | 571 | 62 | 62 | 146 | N/A |
| 6/30/2025 | 563 | 58 | 29 | 113 | N/A |
| 3/31/2025 | 559 | 56 | 72 | 121 | N/A |
| 12/31/2024 | 563 | 54 | 62 | 105 | N/A |
| 9/30/2024 | 564 | 50 | 82 | 103 | N/A |
| 6/30/2024 | 555 | 46 | 76 | 97 | N/A |
| 3/31/2024 | 546 | 39 | 73 | 96 | N/A |
| 12/31/2023 | 546 | 35 | 52 | 73 | N/A |
| 9/30/2023 | 533 | 30 | 25 | 55 | N/A |
| 6/30/2023 | 554 | 28 | 24 | 53 | N/A |
| 3/31/2023 | 570 | 30 | -15 | 12 | N/A |
| 12/31/2022 | 550 | 30 | -33 | -4 | N/A |
| 9/30/2022 | 534 | 29 | -25 | 4 | N/A |
| 6/30/2022 | 487 | 28 | -28 | 0 | N/A |
| 3/31/2022 | 454 | 27 | 3 | 29 | N/A |
| 12/31/2021 | 429 | 28 | 14 | 43 | N/A |
| 9/30/2021 | 420 | 27 | 11 | 40 | N/A |
| 6/30/2021 | 406 | 26 | 34 | 63 | N/A |
| 3/31/2021 | 397 | 23 | 14 | 48 | N/A |
| 12/31/2020 | 386 | 20 | 20 | 49 | N/A |
| 9/30/2020 | 370 | 16 | 10 | 52 | N/A |
| 6/30/2020 | 389 | 17 | 11 | 53 | N/A |
| 3/31/2020 | 387 | 17 | N/A | 54 | N/A |
| 12/31/2019 | 385 | 18 | N/A | 44 | N/A |
| 9/30/2019 | 389 | 19 | N/A | 42 | N/A |
| 6/30/2019 | 380 | 18 | N/A | 22 | N/A |
| 3/31/2019 | 380 | 20 | N/A | 33 | N/A |
| 12/31/2018 | 383 | 23 | N/A | 35 | N/A |
| 9/30/2018 | 380 | 22 | N/A | 24 | N/A |
| 6/30/2018 | 398 | 32 | N/A | 31 | N/A |
| 3/31/2018 | 364 | 21 | N/A | 23 | N/A |
| 12/31/2017 | 361 | 20 | N/A | 31 | N/A |
| 9/30/2017 | 356 | 22 | N/A | 31 | N/A |
| 12/31/2016 | 333 | 15 | N/A | 33 | N/A |
| 9/30/2016 | 331 | 12 | N/A | 39 | N/A |
| 12/31/2015 | 329 | 15 | N/A | 30 | N/A |
Previsiones de crecimiento futuro de los analistas
Ingresos vs. Tasa de ahorro: El pronóstico de crecimiento de los beneficios (19.6% al año) de ACT0 es superior a la tasa de ahorro (2.1%).
Beneficios vs. Mercado: Se prevé que los beneficios (19.6% al año) de ACT0 crezcan más rápidamente que el mercado German (15.1% al año).
Beneficios de alto crecimiento: Se prevé que los beneficios de ACT0 crezcan, pero no significativamente.
Ingresos vs. Mercado: Se prevé que los ingresos (11.5% al año) de ACT0 crezcan más rápidamente que los del mercado German (6.7% al año).
Ingresos de alto crecimiento: Se prevé que los ingresos 11.5% al año) de ACT0 crezcan más despacio que 20% al año.
Previsiones de crecimiento de los beneficios por acción
Rentabilidad financiera futura
ROE futura: Se prevé que la rentabilidad financiera de ACT0 sea alta dentro de 3 años (26%)
Descubre empresas en crecimiento
Análisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/09/18 19:58 |
| Precio de las acciones al final del día | 2026/09/18 00:00 |
| Beneficios | 2026/06/30 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
AlzChem Group AG está cubierta por 9 analistas. 8 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Gerhard Orgonas | Berenberg |
| Julia Winckelmann | BofA Global Research |
| Manuela Stuerzer | Deutsche Bank |